Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.45), $0.19 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $6.88 million versus the consensus estimate of $6.04 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.